JP2018503610A5 - - Google Patents

Info

Publication number

JP2018503610A5

JP2018503610A5 JP2017532648A JP2017532648A JP2018503610A5 JP 2018503610 A5 JP2018503610 A5 JP 2018503610A5 JP 2017532648 A JP2017532648 A JP 2017532648A JP 2017532648 A JP2017532648 A JP 2017532648A JP 2018503610 A5 JP2018503610 A5 JP 2018503610A5

Authority

JP

Japan

Prior art keywords

use according

lymphoma

administered

cell

ibrutinib

Prior art date

2015-12-22

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 12
• 229960001507 ibrutinib Drugs 0.000 claims 12
• XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 12
• 206010028980 Neoplasm Diseases 0.000 claims 10
• 210000003719 b-lymphocyte Anatomy 0.000 claims 10
• 201000011510 cancer Diseases 0.000 claims 10
• 239000003814 drug Substances 0.000 claims 10
• 230000036210 malignancy Effects 0.000 claims 10
• 229940124597 therapeutic agent Drugs 0.000 claims 10
• 206010066476 Haematological malignancy Diseases 0.000 claims 8
• 208000002250 Hematologic Neoplasms Diseases 0.000 claims 8
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 6
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 5
• 229960003347 obinutuzumab Drugs 0.000 claims 4
• 229960002450 ofatumumab Drugs 0.000 claims 4
• 229960005267 tositumomab Drugs 0.000 claims 4
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 3
• 206010025323 Lymphomas Diseases 0.000 claims 3
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 3
• 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
• 208000033766 Prolymphocytic Leukemia Diseases 0.000 claims 3
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 3
• 239000008194 pharmaceutical composition Substances 0.000 claims 3
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 2
• RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 2
• 208000003950 B-cell lymphoma Diseases 0.000 claims 2
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
• 229940126611 FBTA05 Drugs 0.000 claims 2
• 208000034578 Multiple myelomas Diseases 0.000 claims 2
• 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 2
• 239000000739 antihistaminic agent Substances 0.000 claims 2
• 239000002246 antineoplastic agent Substances 0.000 claims 2
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
• 229940127089 cytotoxic agent Drugs 0.000 claims 2
• 201000003444 follicular lymphoma Diseases 0.000 claims 2
• 229910052740 iodine Inorganic materials 0.000 claims 2
• 239000011630 iodine Substances 0.000 claims 2
• 229960002358 iodine Drugs 0.000 claims 2
• 208000032839 leukemia Diseases 0.000 claims 2
• 229950005751 ocrelizumab Drugs 0.000 claims 2
• 229960004641 rituximab Drugs 0.000 claims 2
• UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
• 206010002412 Angiocentric lymphomas Diseases 0.000 claims 1
• 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
• 201000004085 CLL/SLL Diseases 0.000 claims 1
• 206010061818 Disease progression Diseases 0.000 claims 1
• HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
• 208000017604 Hodgkin disease Diseases 0.000 claims 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
• 201000003791 MALT lymphoma Diseases 0.000 claims 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
• 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 claims 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
• 229930012538 Paclitaxel Natural products 0.000 claims 1
• 208000007452 Plasmacytoma Diseases 0.000 claims 1
• 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 claims 1
• 206010065857 Primary Effusion Lymphoma Diseases 0.000 claims 1
• 210000001744 T-lymphocyte Anatomy 0.000 claims 1
• CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
• GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
• 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 1
• 230000000202 analgesic effect Effects 0.000 claims 1
• 229940035676 analgesics Drugs 0.000 claims 1
• 239000000730 antalgic agent Substances 0.000 claims 1
• 230000001387 anti-histamine Effects 0.000 claims 1
• 229940125715 antihistaminic agent Drugs 0.000 claims 1
• 239000003795 chemical substances by application Substances 0.000 claims 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical group OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
• 229960004630 chlorambucil Drugs 0.000 claims 1
• 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 claims 1
• 229960003957 dexamethasone Drugs 0.000 claims 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
• 201000010099 disease Diseases 0.000 claims 1
• 230000005750 disease progression Effects 0.000 claims 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
• 229960003668 docetaxel Drugs 0.000 claims 1
• 229960004679 doxorubicin Drugs 0.000 claims 1
• 229960005167 everolimus Drugs 0.000 claims 1
• 229960000390 fludarabine Drugs 0.000 claims 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
• 208000021173 high grade B-cell lymphoma Diseases 0.000 claims 1
• 229960003445 idelalisib Drugs 0.000 claims 1
• YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 claims 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
• 229960001101 ifosfamide Drugs 0.000 claims 1
• 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 1
• GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
• 229960004942 lenalidomide Drugs 0.000 claims 1
• 208000006116 lymphomatoid granulomatosis Diseases 0.000 claims 1
• KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims 1
• 229960004963 mesalazine Drugs 0.000 claims 1
• 230000001394 metastastic effect Effects 0.000 claims 1
• 206010061289 metastatic neoplasm Diseases 0.000 claims 1
• 239000000203 mixture Substances 0.000 claims 1
• 201000000050 myeloid neoplasm Diseases 0.000 claims 1
• 229960001592 paclitaxel Drugs 0.000 claims 1
• 229960005489 paracetamol Drugs 0.000 claims 1
• 239000000546 pharmaceutical excipient Substances 0.000 claims 1
• 210000004180 plasmocyte Anatomy 0.000 claims 1
• 229960004618 prednisone Drugs 0.000 claims 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 1
• 230000002035 prolonged effect Effects 0.000 claims 1
• 230000005855 radiation Effects 0.000 claims 1
• 201000006845 reticulosarcoma Diseases 0.000 claims 1
• 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
• 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
• 229960000235 temsirolimus Drugs 0.000 claims 1
• QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
• 229960003433 thalidomide Drugs 0.000 claims 1
• 230000001225 therapeutic effect Effects 0.000 claims 1
• 210000001541 thymus gland Anatomy 0.000 claims 1